{"id":"W4414446662","doi":"10.1016/j.ejca.2025.115807","title":"First-line pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma: Health-related quality of life from the randomized phase III KEYNOTE-859 trial","year":2025,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"Trinity College","funders":"Merck Sharp and Dohme","keywords":"Pembrolizumab; Gastroesophageal Junction; Chemotherapy; Interim analysis; Quality of life (healthcare); Interim","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002829936,0.0002883073,0.001769575,0.0002160867,0.0001591853,0.00002954373,0.0002851568,0.000038904,0.0004143296],"category_scores_gemma":[0.001408748,0.00017225,0.000698196,0.000517336,0.0001746424,0.0001270715,0.00004507997,0.0004085866,0.00000167309],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004177477,"about_ca_system_score_gemma":0.0009694966,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004985224,"about_ca_topic_score_gemma":0.0001221301,"domain_scores_codex":[0.9957335,0.0009098714,0.002240457,0.0002741755,0.0005175628,0.0003244247],"domain_scores_gemma":[0.9955197,0.001180085,0.002343052,0.0003070819,0.0004693912,0.0001806823],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9529711,0.0002629542,0.0004725347,0.0001418307,0.00143361,0.00002103262,0.001022515,0.0007707705,0.00003319303,0.00003021212,0.008526203,0.03431403],"study_design_scores_gemma":[0.9739175,0.002917906,0.01821871,0.0004692061,0.0007518659,0.000006147947,0.0004251918,0.000476428,0.00009564499,0.0001028609,0.002505126,0.0001134295],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8898231,0.01563048,0.05759133,0.02841649,0.003271575,0.004619265,0.00008323102,0.00004845166,0.0005160429],"genre_scores_gemma":[0.9901141,0.002330512,0.001341583,0.002388214,0.001195014,0.00004494222,0.00001816329,0.0000448165,0.002522649],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.100291,"threshold_uncertainty_score":0.7024153,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04052856120843663,"score_gpt":0.3508443201991515,"score_spread":0.3103157589907149,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}